Strategic partnerships Leverage existing collaborations with Castle Creek Pharmaceuticals and Precigen to explore co-development or licensing opportunities for FCX-007 and FCX-013, expanding reach in dermatology and orphan disease markets.

Rare disease focus Target specialty clinics and patient advocacy groups focused on recessive dystrophic epidermolysis bullosa and localized scleroderma to position Fibrocell as a leader in autologous cell-based therapies with high unmet need.

Clinical milestones Track progress toward Phase 3 trial design discussions with the FDA and leverage OOPD grant history to accelerate discussions with potential funders or partners for expansion of FCX-007 trials.

Private funding signals With modest revenue and ongoing funding, pursue strategic investors and grant-friendly collaborations that can fund late-stage development and potential commercialization, reducing time-to-market risk.

Market positioning Position FCX-007 and FCX-013 as personalized, localized gene therapies addressing no-approved-cur treatment gaps, and target biopharma players seeking innovative autologous approaches in dermatology and connective tissue diseases.